These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21584421)

  • 1. Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results.
    Titton DC; Silveira IG; Louzada-Junior P; Hayata AL; Carvalho HM; Ranza R; Rezende LS; Pinheiro GC; Santos JL; Miranda JR; Carvalho JF; Bertolo MB; Freire M; Scheinberg MA; Skare TL; Fernandes V; Bianchi W; Laurindo IM
    Rev Bras Reumatol; 2011; 51(2):152-60. PubMed ID: 21584421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs-Data From the Brazilian Registry for Biologics Monitoring.
    Cecconi M; Ranza R; Titton DC; Moraes JCB; Bertolo M; Bianchi W; Brenol C; Carvalho HM; de Castro GRW; Costa IP; Cunha MFL; Duarte Â; Fernandes V; Freire M; Louzada-Junior P; Macieira JC; Miranda JRS; Pereira IA; Pinheiro GRC; Stadler B; Toledo RA; Valim V; Descalzo MA; Pinto RMC; Laurindo I
    J Clin Rheumatol; 2020 Mar; 26(2):73-78. PubMed ID: 32073519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry.
    Busquets N; Tomero E; Descalzo MÁ; Ponce A; Ortiz-Santamaría V; Surís X; Carmona L; Gómez-Reino JJ;
    Rheumatology (Oxford); 2011 Nov; 50(11):1999-2004. PubMed ID: 21856725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.
    Gómez-Reino JJ; Rodríguez-Lozano C; Campos-Fernández C; Montoro M; Descalzo MÁ; Carmona L;
    Ann Rheum Dis; 2012 Mar; 71(3):382-5. PubMed ID: 21998116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland.
    Immonen K; Finne P; Grönhagen-Riska C; Pettersson T; Klaukka T; Kautiainen H; Hakala M
    Amyloid; 2011 Mar; 18(1):25-8. PubMed ID: 21284495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design.
    Hyrich KL
    J Rheumatol Suppl; 2005 Jan; 72():48-50. PubMed ID: 15660468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
    Yazici Y; Erkan D; Paget SA
    Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy.
    Yazici Y; Shi N; John A
    Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
    Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.